McIlrath & Eck’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.98K Hold
32
﹤0.01% 1343
2025
Q4
$2.57K Sell
32
-67
-68% -$5.61K ﹤0.01% 866
2025
Q3
$9.67K Buy
99
+67
+209% +$5.4K ﹤0.01% 633
2025
Q2
$2.23K Hold
32
﹤0.01% 829
2025
Q1
$1.59K Hold
32
﹤0.01% 850
2024
Q4
$2.24K Hold
32
﹤0.01% 859
2024
Q3
$3.35K Hold
32
﹤0.01% 810
2024
Q2
$4.55K Hold
32
﹤0.01% 729
2024
Q1
$3.57K Hold
32
﹤0.01% 771
2023
Q4
$4.15K Sell
32
-26
-45% -$3.58K ﹤0.01% 709
2023
Q3
$9.46K Hold
58
﹤0.01% 556
2023
Q2
$10.6K Buy
+58
New +$8.35K ﹤0.01% 550

Other funds holding ACLS

McIlrath & Eck's ACLS Position: Q1 2026 in Review

McIlrath & Eck held its Axcelis (ACLS) position steady in Q1 2026 at 32 shares worth $2.98K. The position accounts for ﹤0.01% of the portfolio, ranked #1343.

McIlrath & Eck first reported a position in ACLS in Q2 2023 and has held it in 12 quarters since. The position peaked at $10.6K in Q2 2023. 377 funds tracked by Wall St. Rank hold ACLS as of Q1 2026.

  • McIlrath & Eck held 32 shares of Axcelis worth $2.98K as of Q1 2026.
  • McIlrath & Eck left its Axcelis share count unchanged in Q1 2026.
  • Axcelis made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1343 holding.
  • McIlrath & Eck first reported a position in Axcelis in Q2 2023 and has held it in 12 quarters since.
  • McIlrath & Eck's Axcelis position peaked at $10.6K in Q2 2023.
  • 377 funds tracked by Wall St. Rank held Axcelis as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.